Jeremy M. Levin
AUTHOR

Jeremy M. Levin

Tap the gear icon above to manage new release emails.
Dr. Jeremy M. Levin is Executive Chairman of Ovid Therapeutics (NASDAQ: OVID), a biotechnology company developing novel medicines for serious neurological diseases. He is also Chairman Emeritus of the Biotechnology Innovation Organization (BIO), the world’s largest biotechnology trade association. Before founding Ovid, Dr. Levin was President and CEO of Teva Pharmaceutical Industries, leading global operations across more than 140 countries. Earlier, he served on the executive committee of Bristol-Myers Squibb, where he helped architect and execute the company’s “String of Pearls” strategy. He joined Bristol-Myers Squibb from Novartis, where he was Global Head of Strategic Alliances. He has served on the boards of public and private life sciences companies, including H. Lundbeck, and is a member of the Council on Foreign Relations. His work spans biotechnology, branded pharmaceuticals, and generics, with leadership roles in the United States, Europe, and Israel, and deep experience in strategy, capital formation, and corporate transformation. Dr. Levin has been recognized as one of the most influential leaders in biotechnology and has received the Albert Einstein Award for Leadership in Life Sciences and the B’nai B’rith Award for Distinguished Achievement. A physician-scientist by training, he studied at the University of Oxford (BA/MA; DPhil) and the University of Cambridge (MB/BChir), and practiced medicine in university hospitals in England, Switzerland, and South Africa. He edited Biotechnology in the Time of COVID-19. Born and raised on a farm in South Africa, he now divides his time between Manhattan and rural Connecticut today.
Read more Read less

Try Audible membership today. Start enjoying the benefits.

Try Audible for free with an audiobook of your choice.
Auto-renews at AUD $8.99/mo after 30 days. Cancel anytime.

Most Popular

Product list
  • $27.99 or free with 30-day trial